While the anti-sense oligonucleotide oblimersen and the first BH3 mimetic obatoclax showed limited efficacy in early clinical trials, the oral BCL-xL and BCL-2 inhibitor navitoclax showed significant anti-tumoral activity in preclinical AML cells and xenograft models [15,16]. The gene discussed is BCL2; the disease is acute myeloid leukemia.